Breast Cancer Subtypes and Outcomes

Project Summary

Breast cancer heterogeneity presents significant challenges for prognosis and management. This project reclassifies breast tumors using molecular subtypes, including Ki-67, to examine associations with patient survival and clinical outcomes. The study leverages a large institutional cohort with long-term follow-up and detailed clinical and pathological data. By applying advanced statistical models, we aim to generate refined prognostic insights, identify subtype-specific disparities in outcomes, and inform personalized treatment strategies. Results will provide evidence for integrating molecular subtyping into clinical decision-making and national breast cancer management guidelines.

Collaborator

Oncology Center KFSHRC.

Figure

Figure. Molecular Subtype Distribution in Global vs. Saudi Cohorts and Regional Ki-67 Scoring Practices. Panel A: Comparison of molecular subtype distribution between Saudi women diagnosed with breast cancer (2015–2019) and U.S. SEER estimates. Luminal A tumors accounted for only 24% in the Saudi cohort compared to 50% in SEER data, while luminal B and aggressive subtypes (HER2-enriched, TNBC) were more prevalent. Panel B: Regional variation in Ki-67 scoring methods. Percentage-based scoring dominates in Europe and North America, whereas ordinal scales are still commonly used in Saudi Arabia and other GCC countries.

Other Projects by Naser Elkum